AI as an Innovation Platform, Not Just a Supporting Technology

Building an Ecosystem Connecting Data, Technology, and Talent

Noh Yeonhong, President of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association

Noh Yeonhong, President of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association

View original image

New drug development is a "history of perseverance." To deliver a single new drug to patients, countless failures and trial-and-error must be endured. Typically, it takes over 10 years and costs several trillion won, yet the path to success is extremely narrow. Numerous drug candidates disappear in laboratories, and a significant number fail even in clinical trial stages. Reducing such lengthy development periods and high uncertainty has long been an aspiration of the pharmaceutical and bio industries.


Artificial intelligence (AI) is emerging as a breakthrough to overcome these limitations. AI rapidly identifies promising drug candidates by analyzing vast datasets of compounds and genomes, predicts drug efficacy and toxicity, and even optimizes clinical trial participant selection and design. Not only can this increase the likelihood of success in new drug development, it can also dramatically reduce both development time and costs. Now, AI is being established not just as a technology that supports research, but as an innovative platform fundamentally transforming the way new drugs are developed.


The global pharmaceutical industry is also moving swiftly. Major international pharmaceutical companies are building proprietary AI platforms or acquiring AI-driven drug discovery firms to secure future competitiveness. In Korea as well, collaborations between pharmaceutical-bio companies and AI specialists are becoming increasingly active, leading to significant achievements in diverse areas such as drug candidate identification, protein structure prediction, drug repurposing, and clinical trial design.

Reference Image

Reference Image

View original image

AI Holds Special Meaning for Korea


AI carries even greater significance for the Korean pharmaceutical and bio industry. Despite their outstanding research capabilities, domestic companies have been at a disadvantage in global competition due to technological and financial limitations. AI serves as a "game changer" that can help bridge this gap. For Korean companies, AI is not just a tool for improving efficiency—it is an opportunity to transform the landscape of competition. By rapidly analyzing large-scale synthetic compound and genomic data to identify promising candidates, and filtering out those likely to fail early on, development periods and costs can be significantly reduced. As research and development (R&D) productivity increases, the likelihood of overcoming scale limitations through innovation also grows. For Korean firms, which have often been latecomers to the industry, AI is moving beyond being a “lever for catching up” to become a “springboard for advancement.”


To spread this innovation across the entire industry, the efforts of individual companies alone are insufficient. An open ecosystem connecting data, technology, and talent is essential. The Korea Pharmaceutical and Bio-Pharma Manufacturers Association AI Drug Research Institute is building AI-based preclinical and clinical models along with a federated learning platform, and is working to lay the foundations for data standardization and collaborative research through collaboration among industry, academia, research, and hospital partners. Furthermore, efforts are focused on raising industry-wide AI capabilities through initiatives such as self-driving lab training, AI-based clinical trial design, and nurturing specialized talent.


New Momentum Needed Through Swift Resolution of Key Issues


Of course, there remain many challenges to overcome. In the end, AI’s competitiveness derives from data. However, in Korea, the infrastructure to safely utilize compound, genomic, and clinical data is still insufficient. It is urgent to secure high-quality data, establish open sharing systems, foster convergence talent who understand both AI and bio, and develop ecosystems in which IT firms, pharmaceutical companies, and healthcare institutions cooperate based on real-world clinical data (RWD). Above all, a growing body of success stories where AI-discovered drug candidates result in actual new drugs must continue to accumulate.


AI is not merely a future possibility; it is a growth strategy that can propel Korea’s pharmaceutical and bio industry to the center of global competition. Only when technology and data are linked, people are cultivated, and institutional support for innovation is established, will AI become the most powerful engine to turn the new possibilities of "K-Pharma" into reality.



Noh Yeonhong, President of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing